David L. Gillespie

David L. Gillespie

Auto-generated profile, based on publicly available information

David L. Gillespie

Huntsman Cancer Institute, Salt Lake City, UT

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2006 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
RJRandy Jensen
Randy Jensen
BRBrian T. Ragel
Brian T. Ragel
KWKum Whang
Kum Whang
DGDavid Gillespie
David Gillespie

20 August 2008 in Cancer
Verified
Journal Article
Open access
PDF file
JFJeannette R. Flynn
Jeannette R. Flynn
LWLibo Wang
Libo Wang
DGDavid L. Gillespie
David L. Gillespie
GSGregory J. Stoddard
Gregory J. Stoddard
JRJason K. Reid
Jason K. Reid
RJRandy Jensen
Randy Jensen
BACKGROUND.: Regions of hypoxia within glioblastoma multiforme (GBM) are common and may influence a tumor's aggressiveness, response to treatment, and the patient's overall survival. In this study, the authors examined 4 markers of hypoxia (hypoxia‐inducible factor 1 [HIF‐1α], glucose transporter 1 [GLUT‐1], vascular endothelial growth factor [VEGF], and carbonic anhydrase 9 [CA IX]), cellular proliferation and microvascular density (MVD) indices, extent of surgical resection, and preoperative imaging characteristics and compared them with the overall survival rates of adults with GBM.METHODS.: In this retrospective cohort study, patients who had lower grade astrocytomas were compared with patients who had GBM to verify that the methods used could establish differences between tumor grades. By using preoperative imaging, the amount of necrosis was established versus the overall tumor area. The authors also compared preoperative images with postoperative images to define the amount of tumor resected; and they compared molecular markers, proliferation, MVD, and imaging studies with survival among patients who had GBM.RESULTS.: The hypoxia‐regulated molecules (HRMs) and indices for MVD and cellular proliferation were associated significantly with tumor grade. Survival was improved when ≥95% of the tumor was resected. Although the total tumor area was associated with overall survival, no differences were observed when the amount of necrosis or a tumor necrosis index (area of necrosis/area of tumor) was compared with survival. The findings indicated that GLUT‐1 and VEGF were correlated with survival after controlling for age.CONCLUSIONS.: Tumor grade was differentiated with HRMs, MVD, and proliferation, but only GLUT‐1 predicted survival in this group of patients with GBM. The results suggested that GLUT‐1 may be an important independent prognostic indicator. Cancer 2008. © 2008 American Cancer Society.

15 April 2007 in Clinical Cancer Research
Verified
Journal Article
Closed access
DGDavid L. Gillespie
David L. Gillespie
KWKum Whang
Kum Whang
BRBrian T. Ragel
Brian T. Ragel
JFJeannette R. Flynn
Jeannette R. Flynn
DKDavid A. Kelly
David A. Kelly
RJRandy L. Jensen
Randy L. Jensen
Purpose: Higher-grade gliomas are distinguished by increased vascular endothelial cell proliferation and peritumoral edema. These are thought to be instigated by vascular endothelial growth factor, which, in turn, is regulated by cellular oxygen tension. Hypoxia inducible factor-1α (HIF-1α) is a main responder to intracellular hypoxia and is overexpressed in many human cancers, including gliomas.Experimental Design: We investigated the role of HIF-1α in glioma growth in vivo using RNA interference (RNAi) in U251, U87, and U373 glioma cells.Results: We found that RNAi can be used to significantly attenuate glioma growth by reducing HIF-1α levels constitutively using short hairpin RNAs and transiently using small interfering RNAs (siRNA). HIF-1α levels on average were reduced 55% in normoxia and 71% in hypoxia. Vascular endothelial growth factor and GLUT-1 levels were reduced 81% and 71%, respectively, in the stable HIF-1α–reduced clones. These clones showed significant growth attenuation (up to 73%) compared with negative controls when grown in vivo in mouse flanks. Cellular proliferation was also reduced significantly, as determined by MIB-1 staining. Treating gliomas grown in mouse flank transiently with siRNA against HIF-1α by intratumoral injection resulted in a significant reduction of HIF-1α activity. This activity was followed using a hypoxia-responsive luciferase construct that enabled hypoxia imaging in vivo. Tumor volume in these siRNA injection experiments was reduced by 50% over the negative controls.Conclusions: These results indicate that transient RNAi directed against HIF-1α can effectively curb glioma growth in vivo.

1 January 2013 in Neurosurgery
Verified
Journal Article
Closed access
PDF file
RTRheal A. Towner
Rheal A. Towner
RJRandy L. Jensen
Randy L. Jensen
HCHoward Colman
Howard Colman
BVBrian Vaillant
Brian Vaillant
NSNataliya Smith
Nataliya Smith
JWJonathan D. Wren
Jonathan D. Wren
BACKGROUND:. Glioblastoma multiforme (GBM), a high-grade glioma, is characterized by being diffuse, invasive, and highly angiogenic and has a very poor

1 January 2008 in Biomaterials
Verified
Journal Article
Closed access
XWXu-Li Wang
Xu-Li Wang
TNThanh Nguyen
Thanh Nguyen
DGDavid Gillespie
David Gillespie
RJRandy Jensen
Randy Jensen
ZLZheng-Rong Lu
Zheng-Rong Lu

17 October 2019 in JCI Insight
Verified
Journal Article
Open access
PDF file
AGAmber J. Giles
Amber J. Giles
SHShuyu Hao
Shuyu Hao
MPMichelle R. Padget
Michelle R. Padget
HSHua Song
Hua Song
WZWei Zhang
Wei Zhang
DPDeric M. Park
Deric M. Park
Meningiomas are the most common adult primary tumor of the central nervous system, but there are no known effective medical therapies for recurrent meningioma, particularly for World Health Organization grade II and III tumors. Meningiomas arise from the meninges, located outside the blood-brain barrier, and therefore may be directly targeted by antibody-mediated immunotherapy. We found that programmed cell death ligand 1 (PD-L1) was highly expressed in multiple human malignant meningioma cell lines and patient tumor samples. PD-L1 was targeted with the anti–PD-L1 antibody avelumab and directed natural killer cells to mediate antibody-dependent cellular cytotoxicity (ADCC) of PD-L1–expressing meningioma tumors both in vitro and in vivo. ADCC of meningioma cells was significantly increased in target cells that upregulated PD-L1 expression and, conversely, abrogated in tumor cells that were depleted of PD-L1. Additionally, the high-affinity natural killer cell line, haNK, outperformed healthy donor NK cells in meningioma ADCC. Together, these data support a clinical trial designed to target PD-L1 with avelumab and haNK cells, potentially offering a novel immunotherapeutic approach for patients with malignant meningioma.